Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

After obtaining formal institutional review board approval, the charts of 441 patients from 1996 to 2005 receiving low-dose-rate brachytherapy for prostate ... to offer androgen ablation was ...

A report into recurrent prostate cancer by Figg et al ... time to PSA progression seems to occur after two courses of androgen ablation, which might correspond to the time for the evolution ...

“A standard approach for patients with metastatic prostate cancer has been to give drugs that target the androgen receptor, and then if that fails, to give chemotherapy,” Dr. Morris explains. “But ...

In a Maple Grove industrial strip mall unequipped with the beanbag chairs common to Silicon Valley startups, Francis Medical ...

The ADT protocol also included a luteinizing hormone-releasing hormone agonist and anti-androgen for 6 months ... nearly half (48.24%) from prostate cancer. The PSA level at 9 to 10 weeks after ...

The androgen receptor is a key protein that drives the progression of prostate cancer. When androgens (hormones responsible for developing male characteristics) bind to the androgen receptor ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...